Inclusion Criteria:  Documented informed consent; Patients over 18 years of age with active menstrual function; Women with external genital endometriosis, confirmed morphologically and visually during laparoscopic or laparotomy surgery performed 10 years to 2 weeks prior to Day 0;  Patients in the framework of routine clinical practice in accordance with the instructions for use, prior to inclusion in the study, are assigned one of the following therapy regimens:  monotherapy with dienogest 2 mg daily for at least 6 months per os complex treatment with dienogest 2 mg daily for at least 6 months per os in combination with vaginal and rectal suppositories Longidaze® 1 suppository 1 time every 2 days 10 suppositories, and then 1 suppository 1 time in 7 days 17 suppositories for another 120 days; Willingness to use barrier methods of contraception.  Exclusion Criteria:  Women before menarche or after menopause Adenomyosis; Amenorrhea (more than 3 months in a row within 6 months before screening); Patients who are scheduled to undergo surgery for endometriosis during the study; Hormone therapy for endometriosis or the use of aromatase inhibitors within 16 weeks prior to Day 0; Daily use of pain relievers for 7 consecutive days or more due to any other reason other than endometriosis;  6. Participation in clinical trials less than 30 days before the screening visit and / or 5 drug half-lives, whichever is longer.